Loading…

Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation

We report a case with extramedullary tumors affecting the supraclavicular region that presented as a relapse of acute myeloid leukemia (AML) with FLT3-ITD mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Treatment with gilteritinib resulted in remarkable response with d...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research reports 2020-01, Vol.14, p.100219-100219, Article 100219
Main Authors: Kumode, Takahiro, Rai, Shinya, Tanaka, Hirokazu, Espinoza, J. Luis, Kakutani, Hiroaki, Watatani, Yosaku, Minamoto, Shuji, Taniguchi, Yasuhiro, Nakayama, Shoko, Morita, Yasuyoshi, Ashida, Takashi, Matsumura, Itaru
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report a case with extramedullary tumors affecting the supraclavicular region that presented as a relapse of acute myeloid leukemia (AML) with FLT3-ITD mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Treatment with gilteritinib resulted in remarkable response with disappearance of both the medullary and extramedullary tumors. Subsequently, a 2nd allo-HSCT was performed in an attempt to cure his AML and complete molecular response has been sustained with gilteritinib resumption without worsening GVHD. Targeted therapy with gilteritinib for medullary and extramedullary relapse of FLT3-ITD AML could be effective and suitable as a bridging therapy for allo-HSCT.
ISSN:2213-0489
2213-0489
DOI:10.1016/j.lrr.2020.100219